Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | Buy → Neutral | H.C. Wainwright | |
| 9/4/2024 | $9.00 | Buy | H.C. Wainwright |
| 10/24/2023 | $30.00 | Overweight | Cantor Fitzgerald |
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
DENVER, Dec. 29, 2025 (GLOBE NEWSWIRE) -- U.S. equity markets head into the session with a familiar late-cycle mix: capital formation stories, platform expansion in high-growth regions, and strategic deal chatter tied to AI, infrastructure, and healthcare. From an OTC microcap grabbing national airtime to Nasdaq-listed companies securing enterprise AI mandates, today's narrative is about positioning for the next leg of secular growth. Xeriant (OTCQB:XERI): National Spotlight Meets Skunk Works Ambition Xeriant, Inc. (OTCQB:XERI) finds itself in rarefied air after Brig. Gen. (Ret.) Blaine D. Holt, recently appointed President and head of the company's Factor X Research Group, appeared on a
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025. Under the terms of the agreement, ASK Pharm will obtain exclusive rights to develop, manufacture, and commercialize AN9025 in mainland China, Hong Kong and Macao (the "Licensed Territory"). Adlai Nortye will retain worldwide rights to the compound excluding the Licensed Territory. Adlai Nortye is elig
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate in the following investor conferences: The 8th Annual Evercore Healthcare ConferenceFormat: Fireside ChatHost: Jonathan MillerDate and Time: Tuesday, December 2, 2025; 4:15 pm - 4:35 PM EST.Location: Sevilla A, Track 2, the Loews Coral Gables Hotel in Coral Gables, Florida. The 36th Oppenheimer Annual Healthcare Life Sciences ConferenceFormat: Virtual Presen
H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral
H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00
SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear